NCT06128304 ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
| NCT ID | NCT06128304 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Diego |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,436 participants |
| Start Date | 2023-11-13 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,436 participants in total. It began in 2023-11-13 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
While there has been a significant increase in the uptake of antiretroviral therapy among women living with HIV (WLHIV) in many low- and-middle income countries (LMICs), the coverage of cervical cancer screening and treatment (CCST) among WLHIV remains low. This study aims to leverage the available infrastructure for HIV care and treatment programs in Nigeria to integrate cervical cancer screening and treatment and conduct a cluster randomized, hybrid type III trial design to assess the comparative effectiveness of a Core set of implementation strategies versus a Core+ (enhanced) set of implementation strategies to implement cervical cancer screening, onsite treatment, referral and referral completion, treatment, and retention in care among WLHIV. The overarching goal is to improve the health and life expectancy of WLHIV with co-occurring cervical cancer.
Eligibility Criteria
Inclusion Criteria: * Women living with HIV Exclusion Criteria: \-
Contact & Investigator
Gregory Aarons, PhD
PRINCIPAL INVESTIGATOR
University of California, San Diego
Frequently Asked Questions
Who can join the NCT06128304 clinical trial?
This trial is open to female participants only, aged 25 Years or older, up to 64 Years, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06128304 currently recruiting?
Yes, NCT06128304 is actively recruiting participants. Contact the research team at gaarons@health.ucsd.edu for enrollment information.
Where is the NCT06128304 trial being conducted?
This trial is being conducted at La Jolla, United States, Enugu, Nigeria.
Who is sponsoring the NCT06128304 clinical trial?
NCT06128304 is sponsored by University of California, San Diego. The principal investigator is Gregory Aarons, PhD at University of California, San Diego. The trial plans to enroll 2,436 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.